Skip to content
Subscriber Only
Business
Prognosis

CureVac, GSK Report Strong Lab Data for Next-Generation Shot

  • Developers saw strong immune response against variants in rats
  • Human trials for the mRNA vaccine are planned for next quarter
Video player cover image
WATCH: How Do Messenger RNA Vaccines Work?Source: Quicktake
Updated on

CureVac NV and GlaxoSmithKline Plc released positive early data from laboratory testing of their second-generation Covid-19 vaccine, with signs the shot could also provide good protection against some variants of the virus.

Preclinical studies showed strong immune responses in rats, with significant neutralization of variants first discovered in the U.K., South Africa and Denmark, CureVac said in a statement Thursday. Human trials are expected to start in the third quarter.